Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas
Cancers · 18.04.2026 · 18 (8) · 1286
DOI: 10.3390/cancers18081286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 18.04.2026. Verfasst von Moritz Knebel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Otorhinolaryngology, Saarland University, 66421 Homburg, Germany. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Else Kröner-Fresenius-Stiftung, Homburger Forschungsförderungsprogramm.
Abstract (Originalsprache)
Background
The role of immune checkpoint inhibition in treating head and neck squamous cell carcinoma (HNSCC) is expanding, yet response rates to PD-L1 therapy remain inconsistent and generally poor. Although several studies have examined heterogeneous intratumoral PD-L1 expression, the disparity in response to PD-L1 therapy between primary tumors and their associated lymph node metastases remains unclear.
Methods
Primary tumor samples and two matching lymph node metastases were obtained from a cohort of 50 patients and immunohistochemically stained with a PD-L1 antibody. PD-L1 expression, assessed using the combined positive score (CPS) and tumor proportion score (TPS), and immune infiltration, measured with an immunoreactive score (IRS), were compared between the primary tumor and lymph node metastases. These measures were then correlated with other histopathological and clinical features.
Results
PD-L1 expression, evaluated by CPS and TPS, showed no significant differences between the primary tumor and matched lymph node metastases. Discordance relative to established regulatory cut-offs was observed in a subset of patients, affecting 18% (CPS; 95% CI, 8.0–30.0%) and 4% (TPS; 95% CI, 0.0–10.0%) of cases. CPS and TPS values were not influenced by primary tumor subsite or HPV status. Conversely, immune infiltration measured by IRS was significantly affected by primary tumor subsite location. Both HPV tumor status and primary tumor subsite were statistically significantly associated with overall survival.
Conclusions
Our findings highlight variability in PD-L1 expression in HNSCC and may offer context for differential responses of primary tumors and lymph node metastases to immune checkpoint therapy reported in recent clinical studies. These observations support the need for a more comprehensive characterization of PD-L1 expression across tumor sites in head and neck cancer. Further investigation is required to determine whether, and in which settings, reassessment of PD-L1 status in metastatic lesions—including lymph node metastases—may provide additional clinically relevant information when initial testing does not meet established therapeutic cut-offs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Otorhinolaryngology, Saarland University, 66421 Homburg, Germany.
- Department of Otorhinolaryngology, Head and Neck Surgery, Saarland University Medical Center, 66421 Homburg, Germany.
- Department of General and Surgical Pathology, Saarland University Medical Center, 66421 Homburg, Germany.
- Department of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
- Institute of Virology, Saarland University Medical Center, 66421 Homburg, Germany.
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, 66123 Saarbrücken, Germany.
ORCID-Profile: Moritz Knebel, Sandrina Körner, Silke Wemmert, Lukas Alexander Brust, Sigrun Smola, Luc G T Morris, Maximilian Linxweiler
Förderung
- NCI NIH HHS
- Else Kröner-Fresenius-Stiftung
- Homburger Forschungsförderungsprogramm
- Memorial Sloan Kettering Cancer Center
Zitieren
APA
Knebel, M., Klamminger, G. G., Kühn, J. P., Körner, S., Wemmert, S., Brust, L. A., Braun, F., Smola, S., Wagner, M., Ertz, M., Morris, L. G. T., Schick, B., & Linxweiler, M. (2026). Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas. Cancers, 18(8), 1286. https://doi.org/10.3390/cancers18081286
Vancouver
Knebel M, Klamminger GG, Kühn JP, Körner S, Wemmert S, Brust LA, et al. Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas. Cancers. 2026;18(8):1286. doi:10.3390/cancers18081286
BibTeX
@article{Knebel2026,
author = {Knebel, Moritz and Klamminger, Gilbert Georg and Kühn, Jan Philipp and Körner, Sandrina and Wemmert, Silke and Brust, Lukas Alexander and Braun, Felix and Smola, Sigrun and Wagner, Mathias and Ertz, Martin and Morris, Luc G T and Schick, Bernhard and Linxweiler, Maximilian},
title = {Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas},
journal = {Cancers},
year = {2026},
volume = {18},
number = {8},
pages = {1286},
doi = {10.3390/cancers18081286}
}
EUVIMED